---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-042410"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:58:54.555511+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Clearside Q2 net loss $9.1M; Phase 2b ODYSSEY enrollment underway, topline Q3 2024

## Summary
- Net loss $9.1M ($0.15/share) vs $7.8M ($0.13) prior year; cash $35.0M, operations funded into Q3 2024.
- Phase 2b ODYSSEY trial for CLS-AX in wet AMD actively enrolling at ~30 U.S. sites; topline data expected Q3 2024.
- Partner Arctic Vision's NDA accepted in Australia for Arcatus (suprachoroidal treatment of uveitic macular edema).
- R&D expenses $4.9M (down from $5.4M); license revenue $1.0M (up from $0.4M).
- Board Chair changed to Clay B. Thorp; Scientific Advisory Board expanded with three new members.

## SEC filing metadata
- accession: 0000950170-23-042410
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017023042410/0000950170-23-042410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017023042410/clsd-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-042410
- JSON: https://secwatch.observer/filing/0000950170-23-042410.json
- Plain text: https://secwatch.observer/filing/0000950170-23-042410.txt

## Key facts
- Earnings Releases
  Clearside Biomedical, Inc. reported the second quarter ended June 30, 2023 results: revenue $1.0 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $1.0 million
  - Result: reported results
  source text: input on the Company’s research and development programs. Second Quarter 2023 Financial Results • License Revenue: License and other revenue for the second quarter of 2023 was $1.0 million, compared to $0.4 million for the second quarter of 2022. • Cost of Goods Sold: Cost of Goods Sold for the second quarter of 2023 was $0.2 million, compared to $0 for the second
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017023042410/0000950170-23-042410-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.